NasdaqGS:RIGL Earnings and Revenue History March 15th 2025 Zooming In On Rigel Pharmaceuticals' Earnings. One key financial ratio used to measure how well a company converts its p ...

SOUTH SAN FRANCISCO, Calif., March 10, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that ...

Rigel Therapeutics expands oncology portfolio with REZLIDHIA & GAVRETO, sees promising R289 results. Click here to read my ...

Citi analyst Yigal Nochomovitz raised the firm’s price target on Rigel Pharmaceuticals (RIGL) to $55 from $49 and keeps a Buy rating on the ...

Lamar County Sheriff Danny Rigel has documented 40 years of his law enforcement career in a binder. Most officers would use ...

Rigel Pharmaceuticals (NASDAQ:RIGL – Get Free Report) is expected to be issuing its quarterly earnings data after the market ...

Rigel reported a strong third quarter in 2024, with revenue of $55.3 million, significantly beating the consensus estimate of $38.3 million. This performance was largely driven by the impressive ...

Reports Q4 revenue $57.6M, consensus $57.59M. “2024 was a year of significant accomplishments for Rigel. We continued to focus on commercial ...

These increases were partially offset by decreased research and development costs due to the timing of clinical trial activities related to R289, Rigel's dual IRAK 1/4 inhibitor program ...

Rigel reported a strong third quarter in 2024, with revenue of $55.3 million, significantly beating the consensus estimate of $38.3 million. This performance was largely driven by the impressive ...